Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
ASCO Breakthrough 2026
ASCO 2026
ESTRO 2026
AACR 2026
EBCC15
Calendar
View All
Topics
AI in Oncology
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
Departments
ASCO Plenary Series
Adolescent and Young Adult Oncology
Announcements
Art of Oncology
ASCO State Affiliates
At Microphone 1
The Big Casino
Book Reviews
Clinical Trials Resource Guide
Direct From ASCO
Diversity in Oncology
Education in Oncology
End-of-Life Oncology
Expert’s Corner
FDA Update
Geriatrics for the Oncologist
Health-Care Policy
Hematology Expert Review
In Memoriam
Inside the Black Box
Integrative Oncology
In the Clinic
In the Literature
In the News
Journal Spotlight
Law and Ethics
Letters to the Editor
Living a Full Life
OCE Insights
Oncology Worldwide
Perspectives
Palliative Care in Oncology
Patient’s Corner
Pioneers in Oncology
Prevention in Oncology
Profiles
Psychosocial Oncology
Special Reports
Through the Lens of Oncology History
View From The Top
Women in Oncology
Advertisement
Advertisement
Aug
18
Today In Oncology
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
Proton Pump Inhibitor, Antibiotic Exposure Linked to Inferior Durvalumab Outcomes in Unresectable Stage III NSCLC
Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer
Sugar- vs Artificially Sweetened Beverages and Gastric Cancer Risk
High-Risk ERBB2-Negative Breast Cancer Adding Dual Checkpoint Blockade to Neoadjuvant Chemotherapy
View More
Advertisement